ReviewCurrent treatment options in neurology2025
Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.
Review in Current treatment options in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary progressive aphasia(PPA) is a rare neurodegenerative condition and variant presentation of Alzheimer's disease or Frontotemporal Dementia. It is characterized by progressive decline isolated to language functions. PPA provides a model for understanding the anatomy of language, where each cortical language center corresponds to distinct PPA subtypes. Understanding this anatomy and its corresponding PPA subtypes helps clinicians choose testing, interpret imaging, and tailor treatment. These subtypes are termed agrammatic/nonfluent, semantic, and logopenic PPA. Each subtype is probabilistically associated with three proteinopathies: the amyloid and tau of Alzheimer's disease and frontotemporal lobar degeneration due to Tau or TDP-43. We will discuss when biomarker testing is indicated and the nuances of choosing among the increasing array of biomarker tests to improve diagnostic certainty. While medical treatment is limited, there are increasing pharmacologic options for treating Alzheimer's disease. Non-pharmacologic strategies can also be tailored to the patient's specific subtype and caregivers' needs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.